Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by itntdfon Aug 24, 2023 3:43pm
176 Views
Post# 35604247

biden admin to target mrna cancer treatment

biden admin to target mrna cancer treatment
In its bid to fight cancer, the Biden administration this week announced plans to enlist the mRNA technology made famous by COVID-19 vaccines.
 
The idea is to create a platform of mRNA technologies that could turn the immune system against cancer and other diseases.
 
In this case, messenger RNA-based technology would be used to turn off and on multiple genes within immune cells involved in cancer, auto-immune diseases, organ transplant rejection and chronic conditions like long COVID. By contrast, existing vaccines use mRNAs to produce specific proteins to be targeted by the immune system the spike protein of the virus that causes COVID-19, or, with cancer vaccines under development, ones on the surface of tumors.

The new research project led by Emory University in Atlanta will receive up to $24 million from the administration's Advanced Research Projects Agency for Health (ARPA-H).
<< Previous
Bullboard Posts
Next >>